InterMune Inc. (ITMN) gave a disappointing full-year sales view and posted worse-than-expected second-quarter revenue, but the company’s loss narrowed from the year-ago quarter.

The biotech firm expects full-year revenue between $22 million and $27 million, falling short of analyst expectations for 2010 revenue of $28.03 million.

For the second quarter, the company reported a net loss of $25.3 million or 46 cents a share, which compares to the firm’s year-ago loss of $36.7 million or 81 cents a share.

Total revenue fell to $5.9 million, compared with revenue of $7.9 million in the second quarter of 2009.

Analysts polled by Thomson Reuters had predicted a loss of 62 cents a share on revenue of $6.39 billion.

Shares of InterMune fell 42 cents or 3.81% to finish Tuesday’s session at $10.60 a share. The stock was down another 20 cents, nearly 2.00% in after-hours trading.